22 July 2026
On 15 July 2026 the MHRA strengthened its safety warnings for all botulinum toxin type A products after rare cases of iatrogenic botulism, where the toxin's effect spreads beyond the injection site. For injectors this is a prompt to review consent, patient counselling and product sourcing, not a sign the treatment is unsafe when used correctly. Updated product information and patient leaflets now spell out the risk more clearly, and symptoms can appear from a few days up to four weeks after treatment.
What the MHRA botulinum toxin warnings say
On 15 July 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) updated the product information and patient leaflets for all botulinum toxin type A products to highlight the risk of iatrogenic botulism, a rare but serious condition caused by the toxin spreading beyond the injection site. The MHRA has been clear that these products remain safe and effective when used correctly by appropriately qualified practitioners. The change strengthens existing warnings rather than withdrawing or banning any product, and it followed a rise in reported adverse reactions, some of them linked to unlicensed products.
Iatrogenic botulism symptoms and the four-week window
The symptoms to counsel patients on are difficulty swallowing, slurred speech, breathing difficulties and muscle weakness. The MHRA notes these can develop from a few days up to four weeks after treatment, so your aftercare advice should not stop at the first week. Risk may be higher in patients with neurological conditions or a history of dysphagia or aspiration, and it rises with higher doses and with off-label or unapproved injection sites.
Only use UK-authorised products from the regulated supply chain
The MHRA repeated its warning that unlicensed and counterfeit botulinum toxin products do not meet UK safety and quality standards and can significantly increase the risk of serious side effects. Its Criminal Enforcement Unit is investigating cases linked to unlicensed products following a spike in hospital admissions. The practical takeaway for injectors is to buy only UK-authorised products through the regulated pharmacy supply chain, keep batch records, and be able to evidence provenance.
Updating consent, aftercare and Yellow Card reporting
Review your consent form and aftercare sheet so they name iatrogenic botulism, list the warning symptoms, and tell patients to contact NHS 111 or seek urgent care if symptoms appear within four weeks. Confirm your dosing stays within licensed indications and record your clinical reasoning where it does not. Report any suspected adverse reactions through the MHRA Yellow Card scheme, as this is how signals like this one are detected in the first place.
Common questions
- What did the MHRA say about botulinum toxin in July 2026?
- On 15 July 2026 the MHRA strengthened the safety warnings on all botulinum toxin type A products, updating product information and patient leaflets to highlight the rare risk of iatrogenic botulism. It stressed that the products remain safe and effective when used correctly, and separately warned against unlicensed and counterfeit products bought outside the regulated supply chain.
- What are the symptoms of iatrogenic botulism after botulinum toxin?
- The MHRA lists difficulty swallowing, slurred speech, breathing difficulties and muscle weakness. These can appear from a few days up to four weeks after treatment. Patients with these symptoms should contact NHS 111 or seek urgent medical help, and any suspected reaction should be reported through the Yellow Card scheme.
- How should injectors respond to the new botulinum toxin warnings?
- Use only UK-authorised products from the regulated supply chain, keep dosing within licensed indications, and update consent and aftercare to name iatrogenic botulism and its four-week symptom window. Counsel patients clearly, keep batch records, and report any suspected adverse reactions via the MHRA Yellow Card scheme.